OptiNose, Inc. - Common Stock (OQ:OPTN)

Apr 04, 2024 04:01 pm ET
Optinose to Present at the Needham Virtual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the...
Mar 15, 2024 03:34 pm ET
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal...
Mar 07, 2024 07:00 am ET
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2023, and provided recent operational...
Feb 29, 2024 04:40 pm ET
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2023 and corporate updates, before...
Jan 18, 2024 12:00 pm ET
Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced peer-reviewed publication of results from both ReOpen1 and ReOpen2 in the Journal of Allergy and...
Dec 06, 2023 07:00 am ET
Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the U.S. Food and Drug Administration (FDA) has extended by three months the review period of...
Nov 22, 2023 09:00 am ET
Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th...
Nov 09, 2023 07:00 am ET
Optinose Reports Third Quarter 2023 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2023, and provided operational updates. “We...
Oct 27, 2023 08:00 am ET
Optinose Announces Reporting Date for Third Quarter 2023 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2023 and corporate updates, before...
Sep 22, 2023 09:01 am ET
Optinose to Present at the 2023 Cantor Global Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 2023...
Aug 10, 2023 07:00 am ET
Optinose Reports Second Quarter 2023 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2023, and provided operational updates. “We are...
Jul 27, 2023 07:00 am ET
Optinose Announces Preliminary Second Quarter 2023 XHANCE Net Revenue of $19.5 Million
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $19.5 million for the three...
Jun 16, 2023 04:08 pm ET
Optinose Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 100,000 shares of...
Jun 02, 2023 01:00 pm ET
Optinose to Present at the Jefferies Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the...
May 11, 2023 07:00 am ET
Optinose Reports First Quarter 2023 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2023, and provided operational updates. “We are...
May 04, 2023 07:00 am ET
Optinose Announces FDA Acceptance of Supplemental New Drug Application for XHANCE
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) accepted for review its supplemental new drug...
May 01, 2023 04:30 pm ET
Optinose Announces Reporting Date for First Quarter 2023 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2023 and corporate updates, before...
Apr 18, 2023 08:00 am ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of...
Apr 12, 2023 04:00 pm ET
Optinose to Present at the Needham Virtual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the...
Mar 07, 2023 07:00 am ET
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2022, and provided recent operational...
Feb 28, 2023 04:30 pm ET
Optinose Announces Reporting Date for Fourth Quarter 2022 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2022 and corporate updates, before...
Feb 21, 2023 07:00 am ET
Optinose Submits Supplemental New Drug Application for XHANCE Label Expansion
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the submission of its supplemental new drug application (sNDA) to the U.S. Food and Drug...
Jan 31, 2023 07:00 am ET
Optinose Announces CEO Transition and Business Update
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Peter Miller has stepped down as Chief Executive Officer and Board member, and that Ramy...
Dec 15, 2022 04:30 pm ET
Optinose Appoints Paul Spence as Chief Commercial Officer
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Paul Spence as Chief Commercial Officer. Mr. Spence was most recently the Senior...
Dec 09, 2022 08:00 am ET
Optinose Announces Departure of Acting Chief Financial Officer
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Michele Janis, Acting Chief Financial Officer, will leave Optinose to accept a CFO opportunity...
Nov 30, 2022 07:00 am ET
Optinose Announces Corporate Updates and Presentation at the 34th Annual Piper Sandler Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today provided corporate updates and announced that CEO Peter Miller will participate in a fireside chat at the 34th...
Nov 21, 2022 08:30 am ET
Optinose Announces Pricing of Public Offering of Common Stock and Warrants
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 26,320,000 shares of its common stock and warrants...
Nov 21, 2022 06:12 am ET
Optinose Announces Proposed Public Offering of Common Stock and Warrants
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock and accompanying warrants to purchase...
Nov 10, 2022 07:00 am ET
Optinose Reports Third Quarter 2022 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2022, and provided operational updates. “We...
Nov 09, 2022 03:00 pm ET
Optinose Announces ReOpen2 Presentation at the American College of Asthma, Allergy, and Immunology (ACAAI) 2022 Annual Scientific Meeting
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen2 phase 3 clinical trial will be presented at the American College of...
Nov 07, 2022 03:00 pm ET
Optinose Announces Reporting Date for Third Quarter 2022 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2022 and corporate updates, before...
Oct 21, 2022 07:00 am ET
Optinose Announces Late Breaking Abstract Podium Presentation at IDWeek 2022
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its landmark ReOpen phase 3 clinical trial program will be presented at IDWeek 2022...
Sep 06, 2022 12:00 pm ET
Optinose Announces ReOpen1 Abstract Selected for Presentation at the American Rhinologic Society Annual Meeting
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data from its ReOpen1 phase 3 clinical trial will be presented at the American Rhinologic...
Aug 11, 2022 07:00 am ET
Optinose Reports Second Quarter 2022 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2022, and provided operational updates. “We...
Aug 08, 2022 04:20 pm ET
Optinose Announces Reporting Date for Second Quarter 2022 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2022 and corporate updates, before...
Jul 13, 2022 07:00 am ET
Optinose Announces that XHANCE Significantly Reduced Incidence of Exacerbations for Patients with Chronic Sinusitis in Landmark ReOpen Program
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced results of pre-planned analyses from the ReOpen trial program evaluating XHANCE for treatment of...
Jul 08, 2022 07:00 am ET
Optinose Announces Additional Positive Results from ReOpen2 and Initial Results from Pooled Analyses of Both Trials in the ReOpen Program
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced additional results from the ReOpen trial program evaluating XHANCE for treatment of patients with...
Jun 13, 2022 07:00 am ET
Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the statistically significant benefits of XHANCE in the ReOpen2 trial for both the symptoms...
Jun 03, 2022 07:00 am ET
Optinose Announces Departure of Chief Financial Officer
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Keith A. Goldan, Chief Financial Officer, will leave Optinose to accept a CFO opportunity at...
May 12, 2022 07:00 am ET
Optinose Reports First Quarter 2022 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2022, and provided operational updates. “XHANCE...
May 05, 2022 05:00 pm ET
Optinose Announces Reporting Date for First Quarter 2022 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2022 and corporate updates, before...
Apr 26, 2022 08:00 am ET
Optinose Announces Appointment of R. John Fletcher to the Board
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has appointed R. John Fletcher to its Board of Directors as a Class III director. "We are...
Apr 08, 2022 08:30 am ET
Optinose to Present at the Needham Virtual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the...
Mar 08, 2022 07:00 am ET
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2021, and provided recent operational...
Mar 07, 2022 07:00 am ET
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the ReOpen1 clinical trial met both of its co-primary endpoints. A statistically significant...
Mar 04, 2022 02:00 pm ET
Optinose Announces Reporting Date for Fourth Quarter 2021 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2021 and corporate updates, before...
Dec 13, 2021 07:54 am ET
Optinose Announces Appointment of Two New Members to Board of Directors
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Drs. Eric Bednarski and Kyle Dempsey as new directors. Eric and...
Nov 23, 2021 07:00 am ET
Optinose to Present at the Piper Sandler Virtual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
Nov 18, 2021 04:30 pm ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option awards to purchase an aggregate of...
Nov 18, 2021 02:00 pm ET
Optinose Announces Closing of $46.0 Million Public Offering of Common Stock
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of the previously announced underwritten public offering of 28,750,000 shares of its...
Nov 16, 2021 08:01 am ET
Optinose Announces Pricing of Public Offering of Common Stock
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock at a public...
Nov 15, 2021 05:40 pm ET
Optinose Announces Proposed Public Offering of Common Stock
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All...
Nov 15, 2021 04:26 pm ET
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2021, and provided operational updates. “We...
Nov 10, 2021 05:50 pm ET
Optinose Announces Reporting Date for Third Quarter 2021 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the third quarter 2021 and corporate updates, after...
Oct 28, 2021 06:59 am ET
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced it has successfully completed recruitment in the second of two Phase 3b pivotal clinical trials to...
Sep 22, 2021 04:15 pm ET
Optinose to Present at the Cantor Virtual Global Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
Aug 25, 2021 05:00 pm ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of...
Aug 11, 2021 07:00 am ET
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2021, and provided operational updates. “We are...
Jul 30, 2021 08:00 am ET
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced it has successfully completed recruitment in the first of two pivotal clinical trials to evaluate...
Jul 28, 2021 08:00 am ET
Optinose Announces Preliminary Second Quarter 2021 XHANCE Net Revenue of $18.4 Million
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® (fluticasone propionate) net product revenue of $18.4 million for the three...
Jun 24, 2021 08:00 am ET
Optinose Technology Inventor Per Djupesland Named Winner of European Inventor Award 2021 for Industry
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced Dr. Per Djupesland received the European Inventor Award 2021 in the Industry category from the...
Jun 01, 2021 09:00 am ET
Optinose to Present at the Jefferies Virtual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
May 05, 2021 07:00 am ET
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2021, and provided operational updates. “XHANCE...
Apr 28, 2021 08:30 am ET
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2021 and corporate updates, before...
Apr 12, 2021 04:15 pm ET
Optinose to Present at the Needham Virtual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
Mar 03, 2021 07:00 am ET
Optinose Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2020, and provided recent operational...
Feb 17, 2021 05:23 pm ET
Optinose Announces Reporting Date for Fourth Quarter 2020 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the fourth quarter 2020 and corporate updates, before...
Jan 25, 2021 04:30 pm ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted a non-qualified stock option award to purchase 15,000 shares of...
Dec 21, 2020 10:00 am ET
Optinose Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OptiNose, Inc. (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the company has granted non-qualified stock option awards to purchase an aggregate of...
Dec 01, 2020 04:30 pm ET
Optinose Announces Changes to Board of Directors
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Tomas J. Heyman as a new director. Tom has a long-standing track...
Nov 05, 2020 07:00 am ET
Optinose Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the three and nine months ended September 30, 2020, and provided operational...
Oct 22, 2020 07:00 am ET
Optinose Announces Preliminary Third Quarter 2020 XHANCE Net Revenue of $15.4 Million
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced preliminary XHANCE® net product revenues of $15.4 million for the three months ended September 30,...
Sep 14, 2020 08:00 am ET
Optinose to Present at the Cantor Virtual Global Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at...
Aug 14, 2020 08:04 am ET
Optinose Announces Pricing of Public Offering of Common Stock
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the pricing of its previously announced public offering of 6,000,000 shares of common stock at a price to...
Aug 13, 2020 04:26 pm ET
Optinose Announces Proposed Public Offering of Common Stock
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, today announced the commencement of a proposed underwritten public offering of shares of its common stock. All of the...
Aug 04, 2020 07:00 am ET
Optinose Reports Second Quarter 2020 Financial Results and Recent Operational Highlights 
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2020, and provided operational updates. “XHANCE...
Jul 30, 2020 04:01 pm ET
Optinose Announces Reporting Date for Second Quarter 2020 Financial Results
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the second quarter 2020 and corporate updates, before...
Jul 29, 2020 04:01 pm ET
Optinose names Catherine E. Owen as Director
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Catherine E. Owen as a new director. Catherine currently serves as...
Jul 08, 2020 04:15 pm ET
Optinose Announces XHANCE Co-Promotion Agreement with Kaléo
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement with kaléo, a pharmaceutical company dedicated to building innovative...
Jun 30, 2020 08:00 am ET
Optinose Announces Anti-COVID-19 Product Candidate
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced initiation of development of a new product candidate, OPN-019. OPN-019 will combine the Company’s...
Jun 22, 2020 08:30 am ET
Optinose to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
Jun 19, 2020 10:00 am ET
Optinose Named a 2020 Best Place to Work by Philadelphia Business Journal
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for...
May 27, 2020 04:30 pm ET
Optinose to Host its Annual Meeting of Stockholders in Virtual Format
OptiNose, Inc. (NASDAQ:OPTN) today announced that due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic and recommendations and orders from federal and state governmental authorities, its Annual Meeting...
May 26, 2020 09:00 am ET
Optinose to Present at the 2020 Jefferies Virtual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
May 14, 2020 04:15 pm ET
Optinose to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
May 07, 2020 04:01 pm ET
Optinose Reports First Quarter 2020 Financial Results and Operational Updates
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2020, and provided operational updates. “Since...
Apr 30, 2020 04:15 pm ET
Optinose to Report First Quarter 2020 Financial Results and Corporate Updates on May 7, 2020
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2020 and corporate updates, after...
Mar 05, 2020 06:30 am ET
Optinose Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2019, and provided recent operational...
Feb 27, 2020 04:30 pm ET
Optinose to Report Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates on March 5, 2020
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter and year-end 2019, before market...
Feb 19, 2020 07:00 am ET
Optinose Appoints Victor Clavelli as Chief Commercial Officer
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the appointment of Victor M. Clavelli as Chief Commercial Officer. Mr. Clavelli joins Optinose from...
Dec 17, 2019 08:30 am ET
Optinose Announces Peer-Reviewed Publication of the Fourth Major XHANCE Registration Trial
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that results of the Phase 3 EXHANCE-3 trial were published in the peer-reviewed journal Rhinology1,...
Nov 26, 2019 04:01 pm ET
Optinose to Present at the Piper Jaffray 31st Annual Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
Nov 21, 2019 09:00 am ET
Optinose Announces Pricing of Public Offering of Common Stock
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public...
Nov 20, 2019 04:00 pm ET
Optinose Announces Proposed Public Offering of Common Stock
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it and certain selling stockholders intend to offer and sell shares of its common stock in an...
Nov 12, 2019 04:01 pm ET
Optinose Reports Third Quarter 2019 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2019, and provided recent operational...
Nov 01, 2019 08:00 am ET
Optinose to Report Third Quarter 2019 Financial Results and Corporate Updates on November 12, 2019
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2019, after market close on...
Oct 04, 2019 08:00 am ET
Optinose Appoints Michael Richardson to New Position of Vice President, Business Development
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported the creation of a new role of Vice President, Business Development and appointment of Michael...
Sep 27, 2019 08:00 am ET
Optinose to Present at the 2019 Cantor Global Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present a company overview and business update at the...
Sep 26, 2019 08:15 am ET
Currax™ Pharmaceuticals LLC Announces First Acquisition: Acquires North American Rights to ONZETRA® Xsail®
MORRISTOWN, N.J., Sept. 26, 2019 /PRNewswire/ -- Currax Pharmaceuticals LLC, a specialty biopharmaceutical company with both Branded and generic business units, announced today a deal whereby Currax obtained patent rights to ONZETRA® Xsail® (sumatriptan nasal powder) in North America from OptiNose AS, a subsidiary of OptiNose, Inc. (Nasdaq: OPTN).
Sep 26, 2019 07:00 am ET
OptiNose Announces License Agreement Related to ONZETRA XSAIL
OptiNose, Inc. (Optinose) (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the signing of an agreement between its Norway-based subsidiary OptiNose AS and...
Sep 17, 2019 04:01 pm ET
Optinose Announces Departure of Chief Commercial Officer
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the departure of its Chief Commercial Officer, Tom Gibbs. Mr. Gibbs will be leaving the Company...
Sep 12, 2019 04:05 pm ET
Optinose Announces $150 Million Debt Financing from Pharmakon
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported that it has entered into a note purchase agreement for up to $150 million of senior secured notes...
Aug 12, 2019 04:02 pm ET
Optinose Reports Second Quarter 2019 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2019, and provided recent operational highlights....
Aug 01, 2019 04:30 pm ET
Optinose to Report Second Quarter 2019 Financial Results and Corporate Updates on August 12, 2019
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the second quarter 2019, after market close on...
Jun 20, 2019 08:00 am ET
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2019 BMO Capital Markets Prescriptions...
Jun 19, 2019 04:30 pm ET
Optinose Named a 2019 Best Place to Work by Philadelphia Business Journal
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for...
May 09, 2019 07:00 am ET
Optinose Reports First Quarter 2019 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2019, and provided recent operational highlights....
Apr 25, 2019 07:00 am ET
Optinose to Report First Quarter 2019 Financial Results and Corporate Updates on May 9, 2019
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2019, before market open on...
Apr 08, 2019 08:20 am ET
Market Trends Toward New Normal in NIKE, Harley-Davidson, Knowles, Sorrento Therapeutics, OptiNose, and Columbia Sportswear — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of NIKE, Inc. (NYSE:NKE), Harley-Davidson, Inc. (NYSE:HOG), Knowles...
Mar 06, 2019 07:00 am ET
 Optinose Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the year ended December 31, 2018, and provided recent operational highlights....
Feb 27, 2019 07:00 am ET
Optinose to Report Fourth Quarter 2018 Financial Results and Corporate Updates on March 6, 2019
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the fourth quarter 2018, before market open on...
Feb 19, 2019 07:00 am ET
Optinose Announces Issuance of Four Additional U.S. Patents Covering XHANCE
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the United States Patent and Trademark Office (USPTO) recently issued four patents covering XHANCE®...
Feb 15, 2019 07:00 am ET
Optinose to Highlight Data at the 2019 AAAAI Annual Meeting in San Francisco
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will present clinical and health economic outcomes data at the 2019 American Academy of...
Feb 04, 2019 07:00 am ET
Optinose Announces License Agreement
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a license agreement...
Dec 11, 2018 07:50 am ET
Investor Expectations to Drive Momentum within eBay, Pulse Biosciences, Evolus, Weibo, OptiNose, and The Descartes Systems Group — Discovering Underlying Factors of Influence
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of eBay Inc. (NASDAQ:EBAY), Pulse Biosciences, Inc (NASDAQ:PLSE), Evolus,...
Dec 11, 2018 07:00 am ET
Optinose Announces Update to License Agreement with Avanir Pharmaceuticals for ONZETRA XSAIL  
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company received written notice from Avanir Pharmaceuticals, Inc. of its election to terminate...
Dec 10, 2018 07:00 am ET
Optinose Announces First Patient Enrolled in Clinical Trial of XHANCE for Chronic Sinusitis
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, announced today the enrollment of the first patient in a global clinical trial to evaluate the safety and efficacy...
Dec 05, 2018 04:30 pm ET
Optinose to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2018 Prescriptions for Success...
Nov 13, 2018 07:00 am ET
Optinose Reports Third Quarter 2018 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended September 30, 2018, and provided recent operational...
Oct 31, 2018 04:30 pm ET
Optinose to Report Third Quarter 2018 Financial Results and Corporate Updates on November 13, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the third quarter 2018, before market open on...
Oct 22, 2018 08:10 am ET
Detailed Research: Economic Perspectives on Caseys General Stores, Evolus, OptiNose, Xunlei, Molina Healthcare, and Frontline — What Drives Growth in Today's Competitive Landscape
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Caseys General Stores, Inc. (NASDAQ:CASY), Evolus, Inc. (NASDAQ:EOLS),...
Oct 03, 2018 07:00 am ET
Optinose to Highlight Data at Two Upcoming Scientific Meetings
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that data concerning its product XHANCE® will be presented at the American Rhinologic Society (ARS)...
Sep 24, 2018 04:30 pm ET
Optinose to Present at the 2018 Cantor Global Healthcare Conference
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 2018 Cantor Global Healthcare...
Aug 14, 2018 08:28 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against OptiNose, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of OptiNose, Inc. (“OptiNose” or “the Company”) (NASDAQ:
Aug 14, 2018 12:48 pm ET
INVESTOR ALERT: Investigation of OptiNose Announced by Holzer & Holzer
Holzer & Holzer, LLC is investigating whether OptiNose, Inc. (“OptiNose” or the “Company”) (NASDAQ: OPTN) complied with the federal securities laws. On August 14, 2018, OptiNose issued financial results for the quarter ended June 30, 2018 and reported a net loss of $24.6 million. The price of OptiNose stock fell significantly following the report.
Aug 14, 2018 07:00 am ET
Optinose Reports Second Quarter 2018 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended June 30, 2018, and provided recent operational highlights....
Aug 07, 2018 05:00 pm ET
Optinose to Report Second Quarter 2018 Financial Results and Corporate Updates on August 14, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the second quarter 2018, before market open on...
Jul 02, 2018 05:11 pm ET
Optinose Named a 2018 Best Place to Work by Philadelphia Business Journal
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that the Company has been named one of the Philadelphia Business Journal’s “Best Places to Work” for...
Jun 21, 2018 04:30 pm ET
Optinose Announces Publication of Pivotal Efficacy and Long-Term Safety Data for XHANCE in Peer Reviewed Journals
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that results of the Phase 3 NAVIGATE II trial and the EXHANCE-12 trial were published in...
Jun 15, 2018 02:05 pm ET
Optinose CEO Peter Miller and President and COO Ramy Mahmoud Named EY Life Sciences Entrepreneur Of The Year 2018 in Greater
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President and Chief Operating Officer Ramy Mahmoud, MD, MPH, have been...
Jun 11, 2018 04:25 pm ET
Optinose Announces Closing of Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Common Shares
OptiNose, Inc. (NASDAQ:OPTN), announced today the closing of its underwritten public offering of 5,750,000 of its common shares at a price to the public of $22.25 per common share, including 750,000 common shares sold pursuant to the underwriters'...
Jun 06, 2018 08:21 pm ET
Optinose Announces Pricing of Public Offering of Common Stock
OptiNose, Inc. (NASDAQ:OPTN), announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $22.25 per share, before underwriting discounts. The offering consists of 2,500,000...
Jun 04, 2018 04:56 pm ET
Optinose Announces Launch of Public Offering of Common Stock
OptiNose, Inc. (NASDAQ:OPTN), announced today that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) and commenced a proposed underwritten public offering of 4,500,000 shares of its common...
May 14, 2018 07:00 am ET
Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2018, and provided recent operational highlights....
May 07, 2018 08:00 am ET
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018
Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will release financial results for the first quarter 2018, before market open on Monday,...
Apr 23, 2018 04:01 pm ET
Optinose CEO Peter Miller and President/COO Ramy Mahmoud Named EY Entrepreneur of the Year 2018 Finalists in the Greater Philadelphia Area
YARDLEY, Pa., April 23, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that CEO Peter Miller and President/COO Ramy Mahmoud, MD, MPH,...
Mar 15, 2018 04:01 pm ET
Optinose Named Emerging Company of the Year by Life Sciences Pennsylvania
YARDLEY, Pa., March 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Optinose was named the Emerging Company of the Year...
Mar 13, 2018 07:00 am ET
Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights
Optinose expects early April availability of XHANCE in retail pharmacies
Mar 06, 2018 04:01 pm ET
Optinose to Report Fourth Quarter and Full Year 2017 Financial Results and Corporate Updates on March 13, 2018
Conference Call and Webcast Scheduled for Tuesday, March 13 at 8:00 a.m. Eastern Time
Feb 27, 2018 07:00 am ET
Optinose to Highlight Data at the 2018 AAAAI/WAO Joint Congress
Optinose expects to make XHANCE (fluticasone propionate) nasal spray 93mcg available through retail pharmacies in early April 2018
Feb 22, 2018 04:01 pm ET
Optinose names Sandra L. Helton as Director and Chairperson of the Company’s Audit Committee
YARDLEY, Pa., Feb. 22, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced its Board of Directors has named Sandra L. Helton as...
Feb 20, 2018 04:01 pm ET
Peter Miller Named Frank Baldino Bioscience CEO of the Year by Life Sciences Pennsylvania
Optinose Also Named as Finalist for Emerging Company of the Year
Feb 15, 2018 08:00 am ET
Optinose to Present at the 2018 RBC Capital Markets Healthcare Conference
YARDLEY, Pa., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the...
Feb 09, 2018 08:00 am ET
Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference
YARDLEY, Pa., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the...
Jan 02, 2018 08:00 am ET
Optinose Announces $100 Million Debt Financing from Athyrium Capital Management
YARDLEY, Pa., Jan. 02, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that it has entered into a $100 million debt financing...
Dec 11, 2017 08:15 am ET
Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors
WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of William F. Doyle and...
Dec 07, 2017 04:05 pm ET
Optinose to Present at BMO Capital Markets Prescription for Success Healthcare Conference
YARDLEY, Pa., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the BMO Capital Markets 2017...
Nov 27, 2017 04:05 pm ET
Optinose Reports Third Quarter 2017 Financial Results and Recent Operating Highlights
FDA Approval of XHANCE™, Successful IPO, Leadership Team Expanded to Drive Commercialization
Nov 20, 2017 07:30 am ET
Optinose to Report Third Quarter 2017 Financial Results and Operational Highlights on November 27, 2017
YARDLEY, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that the Company will report its third quarter 2017 financial results and recent operational...
Nov 17, 2017 07:30 am ET
Optinose to Present at Piper Jaffray Healthcare Conference
YARDLEY, Pa., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the 29th Annual Piper Jaffray...
Nov 08, 2017 08:00 am ET
Optinose to Present at Jefferies 2017 London Healthcare Conference
YARDLEY, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive Officer Peter Miller will present at the Jefferies 2017 London Healthcare...
Oct 17, 2017 04:01 pm ET
Optinose Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
YARDLEY, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $16.00 per share, which includes an additional 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The aggregate gross proceeds to Optinose fr...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.